Proposals by India's Ministry of Chemicals and Petrochemicals to monitor pharmaceutical pricing following the notification this month of the new Drug Prices Control Order (Marketletter January 16) have received a setback. This is due to the Finance Ministry expressing its opposition to the Chemicals Ministry's plan to establish a new authority of experts, whose responsibility would be to review pharmaceutical prices on an annual basis.
The new body, to be named the National Pharmaceutical Pricing Authority, would also be expected to assist in the implementation of the new DPCO. Announcing the modifications to the 1986 drug policy in September 1994, Ministry officials had stated that in order to achieve uniformity in prices of widely-used drug products, ceiling prices should be established for commonly-available standard pack sizes of price-controlled formulations, and that these ceiling prices should be binding on all manufacturers, including the smaller enterprises.
Details Of the New DPCO The new DPCO sets price controls on 76 medicines which account for almost 50% of the national retail pharmaceutical market. Previously, 143 products were under price control. 83 items which previously carried price restrictions have also now been decontrolled. Products for which there is considered to be adequate market competition are not under price control, and according to the Marketletter's New Delhi correspondent, at least five bulk drug producers and 10 formulators within the retail market have been kept out of price control.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze